The Riverside Company, a global investment firm focused on the smaller end of the middle market, has announced that BioDue S.p.A (BioDue), a portfolio company of its affiliated European fund, has signed a definitive agreement to invest in Biokosmes and Rolf Kullgren, a business unit of Venture Life Group plc (VLG), a UK-quoted consumer healthcare business. The investment marks the second add-on since Riverside’s investment in 2023, for BioDue, an Italian food supplements, medical devices and cosmetics business. Closing is subject to customary conditions including approvals by the competent regulatory authorities.

Founded in 2010, VLG and its subsidiaries manufacture and supply consumer healthcare products including medical devices, cosmetics and food supplements. BioDue is acquiring VLG’s contract development and manufacturing organization (CDMO) business unit, including some of VLG’s medical device technical files portfolio. At closing, VLG will enter into a long-term manufacturing agreement with BioDue, under which it will manufacture a number of its products on an exclusive basis.

Read full press release here.